The current role of statin therapy in the treatment of atrial fibrillation

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2013, Pages 9-13

  Naji, Franjo ^a   Sabovic, Miso ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Atrial fibrillation; Atrial remodeling; Heart failure; Inflammation; Ischemic heart disease; Paroxysmal atrial fibrillation; Primary prevention; Radiofrequency ablation secondary prevention; Statins

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; PLACEBO; ROSUVASTATIN;

CARDIOVERSION; CATHETER ABLATION; CORONARY ARTERY BYPASS GRAFT; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PAROXYSMAL HEART ATRIUM FIBRILLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ATRIAL FIBRILLATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84873118061     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/1871525711311010004     Document Type: Review

References (60)

1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; Prendergast, B.; Heidbuchel, H.; Alfieri, O.; Angelini, A.; Atar, D.; Colonna, P.; De Caterina, R.; De Sutter, J.; Goette, A.; Gorenek, B.; Heldal, M.; Hohloser, S.H.; Kolh, P.; Le Heuzey, J.Y.; Ponikowski, P.; Rutten, F.H.; ESC Committee for Practice Guidelines; Vahanian, A.; Auricchio, A.; Bax, J.; Ceconi, C.; Dean, V.; Filippatos, G.; Funck-Brentano, C.; Hobbs, R.; Kearney, P.; McDonagh, T.; Popescu, B.A.; Reiner, Z.; Sechtem, U.; Sirnes, P.A.; Tendera, M.; Vardas, P.E.; Widimsky, P.; Document Reviewers; Vardas, P.E.; Agladze, V.; Aliot, E.; Balabanski, T.; Blomstrom-Lundqvist, C.; Capucci, A.; Crijns, H.; Dahlöf, B.; Folliguet, T.; Glikson, M.; Goethals, M.; Gulba, D.C.; Ho, S.Y.; Klautz, R.J.; Kose, S.; McMurray, J.; Perrone Filardi, P.; Raatikainen, P.; Salvador, M.J.; Schalij, M.J.; Shpektor, A.; Sousa, J; Stepinska, J.; Uuetoa, H.; Zamorano, J.L.; Zupan, I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 2010, 12(10), 1360-1420.
2. Stewart, S.; Hart, C.L.; Hole, D.J.; McMurray, J.J. Population prevalence, incidence and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart, 2001, 86, 516-521.
3. Stewart, S.; Hart, C.L.; Hole, D.J.; McMurray, J.J. A populationbased study of the long-term risks associated with atrial fibrillation: 20 year follow-up of the Renfrew/Paisley study. Am. J. Med., 2002, 113(5), 359-364.
4. Miyasaka, Y.; Barnes, M.E.; Gersh, B.J.; Cha, S.S.; Bailey, K.R.; Abhayaratna, W.P.; Seward, J.B.; Tsanq, T.S. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation, 2006, 114(2), 119-125.
5. Lloyd-Jones, D.M.; Wang, T.J.; Leip, E.P.; Larson, M.G., Levy, D.; Vasan, R.S.; D'Agostino, R.B.; Massaro, J.M.; Beiser, A.; Wolf, P.A.; Benjamin, E.J. Lifetime risk for developement of atrial fibrillation: the Framingham Heart Study. Circulation, 2004, 110(9), 1042-1046.
6. Camm A.J.; Lu{double acute}sher, T.F.; Serruys, P.; Camm, A.J.; Kirchhof, P.; Lip, G.Y.H.; Savelieva, I.; Ernst, S. Atrial fibrillation. In: The ESC Textbook of Cardiovascular Medicine; Camm, A.J.; Lu{double acute}sher, T.F.; Serruys, P.W.; Eds.; Blackwell Publishing Ltd: Oxford, 2009; pp. 1069-1132.
7. Naji, F.; Vokac, D.; Kanic, V.; Sabovic, M. Optimal timing of electrical cardioversion in patients with persistent atrial fibrillation. Med. Sci. Monit., 2010, 16(10), CR464-468.
8. Go, A.S.; Hylek, E.M.; Phillips, K.A.; Chanq, Y.; Henault, L.E.; Selby, J.V.; Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285(18), 2370-2375.
9. Mathew, J.P.; Fontes, M.L.; Tudor, I.C.; Ramsay, J.; Duke, P.; Mazer, C.D.; Barash, P.G.; Hsu, P.H.; Mangano, D.T. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA, 2004, 291(14), 1720-1729.
10. Savelieva, I.; Kakouros, N.; Kourliouros, A.; Camm, A.J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace, 2011, 13(13), 308-328.
11. Ishii, Y.; Schuessler, R.B.; Gaynor, S.L.; Yamada, K.; Fu, A.S.; Boineau, J.P.; Damiano, R.J. Jr. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation, 2005, 111(22), 2881-2888.
12. Frustaci, A.; Chimenti, C.; Bellocci, F.; Morgante, E.; Russo, M.A.; Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96(4), 1180-1184.
13. Marcus, G.M.; Whooley, M.A.; Glidden, D.V.; Pawlikowska, L.; Zaroff, J.G.; Olgin, J.E. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am. Heart J., 2008, 155(2), 303-309.
14. Liu, T.; Li, L.; Korantzopoulos, P.; Goudevenos, J.A.; Li, G. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a metaanalysis. J. Am. Coll. Cardiol., 2007, 49(15), 1642-1648.
15. Dobrev, D.; Nattel, S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J. Cardiovasc. Pharmacol., 2008, 52(4), 293-299.
16. Aviles, R.; Martin, D.; Apperson-Hansen, C.; Houghtaling, P.L.; Rautaharju, P.; Kronmal, R.A.; Tracy, R.P.; Van Wagoner, D.R.; Psaty, B.M.; Lauer, M.S.; Chung, M.K. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108(24), 3006-3010.
17. Dernellis, J.; Panaretou, M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiologica, 2001, 56(6), 375-380.
18. Abdelhadi, R.H.; Gurm, H.S.; Van Wagoner, D.R.; Chung, M.K. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am. J. Cardiol., 2004, 93(9), 1176-1178.
19. Goette, A.; Staack, T.; Rocken, C.; Arndt, M.; Geller, J.C.; Huth, C.; Ansorge, S.; Klein, H.U.; Lendeckel, U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol., 2000, 35(6), 1669-1677.
20. Korantzopoulos, P.; Kolettis, T.; Siogas, K.; Goudevenos, J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med. Sci. Monit., 2003, 9(9), RA225-229.
21. Milliez, P.; Girerd, X.; Plouin, P.F.; Blacher, J.; Safar, M.E.; Mourad, J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol., 2005, 45(8), 1243-1248.
22. Tsai, C.T.; Chiang, F.T.; Tseng, C.D.; Hwang, J.J.; Kuo, K.T.; Wu, C.K.; Yu, C.C.; Wang, Y.C.; Lai, L.P.; Lin, J.L. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J. Am. Coll. Cardiol., 2010, 55(8), 758-770.
23. Nakano, Y.; Niida, S.; Dote, K.; Takenaka, S.; Hirao, H.; Miura, F.; Ishida, M.; Shingu, T.; Sueda, T.; Yoshizumi, M.; Chayama, K. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J. Am. Coll. Cardiol., 2004, 43(5), 818-825.
24. Naji, F.; Suran, D.; Kanic, V.; Vokac, D.; Sabovic, M. High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion. Int. Heart J., 2010, 51(1), 30-33.
25. Reilly, S.N.; Jayaram, R.; Nahar, K.; Antoniades, C.; Verheule, S.; Channon, K.M.; Alp, N.J.; Schotten, U.; Casadei, B. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation, 2011, 124(10), 1107-1117.
26. Laufs, U.; Fata, V.L.; Liao, J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated downregulation of endothelial nitric oxide synthase. J. Biol. Chem., 1997, 272(50), 31725-31729.
27. Romano, M.; Mezzetti, A.; Marulli, C.; Ciabattoni, G.; Febo, F.; Di Ienno, S.; Roccaforte, S.; Vigneri, S.; Nubile, G.; Milani, M.; Davì, G. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J. Investig. Med., 2002, 48(3), 183-189.
28. Lin, C.P.; Chen, Y.H.; Lin, W.T.; Leu, H.B.; Liu, T.Z.; Huang, S.L.; Chen, J.W. Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis. Eur. J. Clin. Invest., 2008, 38(2), 106-116.
29. Vaughan, C.J.; Gotto, A.M. Jr; Basson, C.T. The evolving role of statins in themanagement of atherosclerosis. J. Am. Coll. Cardiol., 2000, 35(1),1-10.
30. Romano, M.; Diomede, L.; Sironi, M.; Massimiliano, L.; Sottocorno, M.; Polentarutti, N.; Guglielmotti, A.; Albani, D.; Bruno, A.; Fruscella, P.; Salmona, M.; Vecchi, A.; Pinza, M.; Mantovani, A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest., 2000, 80(7), 1095-1100.
31. Liang, Y.J.; Shyu, K.G.; Wang, B.W.; Lai, L.P. Simvastatin inhibits C-reactive protein-induced proinflammatory changes in endothelial cells by decreasing mevolanate pathway products. Cardiology, 2008, 110(3), 182-190.
32. Savelieva, I.; Kourliouros, A.; Camm, J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch. Pharmacol., 2010, 381(3), 1-13.
33. Kang, B.Y.; Mehta, J.L. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc. Pharmacol. Ther., 2009, 14(4), 283-291.
34. Kumagai, K.; Nakashima, H.; Saku, K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc. Res., 2004, 62(1), 105-111.
35. Hanna, I.R.; Heeke, B.; Bush, H.; Brosius, L.; King-Hageman, D.; Dudley, S.C. Jr; Beshai, J.F.; Langberg, J.J. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm, 2006, 3(8), 881-886.
36. Maggioni, A.P.; Fabbri, G.; Lucci, D.; Marchioli, R.; Franzosi, M.G.; Latini, R.; Nicolosi, G.L.; Porcu, M.; Cosmi, F.; Stefanelli, S.; Tognoni, G.; Tavazzi, L.; GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur. Heart J., 2009, 30(19), 2327-2336.
37. Dotani M.I.; Elnicki D.M.; Jain A.C.; Gibson C.M. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am. J. Cardiol., 2000, 86(10), 1128-1130.
38. Marin, F.; Pascual, D.A.; Roldan, V.; Arribas, J.M.; Ahumada, M.; Tornel, P.L.; Oliver, C.; Gómez-Plana, J.; Lip, G.Y.; Valdés, M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am. J. Cardiol., 2006, 97(1), 55-60.
39. Lertsburapa, K.; White, C.M.; Kluger, J.; Faheem, O.; Hammond, J.; Coleman, C.I. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J. Thorac. Cardiovasc. Surg., 2008, 135(2), 405-411.
40. Kourliouros, A.; De Souza, A.; Roberts, N.; Marciniak, A.; Tsiouris, A.; Valencia, O.; Camm, J.; Jahangiri, M. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann. Thorac. Surg., 2008, 85(5), 1515-1520.
41. Song, Y.B.; On, Y.K.; Kim, J.H.; Shin, D.H.; Kim, J.S.; Sung, J.; Lee, S.H.; Kim, W.S.; Lee, Y.T. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am. Heart J., 2008, 156(2), 373. e9-16.
42. Sun, Y.; Ji, Q.; Mei, Y.; Wang, X.; Feng, J.; Cai, J.; Chi, L. Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. Int. Heart J., 2011, 52(1), 7-11.
43. Chen, W.T.; Krishnan, G.M.; Sood, N.; Kluger, J.; Coleman, C.I. Effects of statins on atrial fibrillation after cardiac surgery: a duration-and dose-response meta-analysis. J. Thorac. Cardiovasc. Surg., 2010, 140(2), 364-372.
44. Pellegrini, C.N.; Vittinghoff, E.; Lin, F.; Hulley, S.B.; Marcus, G.M. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart, 2009, 95(9), 704-708.
45. Vedre, A.; Gurm, H.S.; Froehlich, J.B.; Kline-Rogers, E.; Montalescot, G.; Gore, J.M.; Brieger, D.; Quill, A.L.; Eagle, K.A.; GRACE Investigators. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am. J. Cardiol., 2009, 104(12), 1613-1617.
46. Ozaydin, M.; Turker, Y.; Erdogan, D.; Karabacak, M.; Dogan, A.; Varol, E.; Gonul, E.; Altinbas, A. The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int. J. Cardiol., 2008, 141(2), 147-150.
47. Liu, T.; Li, G.; Korantzopoulos, P.; Goudevenos, J.A. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int. J. Cardiol., 2008, 126(2), 160-170.
48. Rahimi, K.; Emberson, J.; McGale, P.; Majoni, W.; Merhi, A.; Asselbergs, F.W.; Krane, V.; Macfarlane, P.W.; PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ, 2011, 342, d1250.
49. Gillis, A.M.; Morck, M.; Exner, D.V.; Soo, A.; Rose, M.S.; Sheldon, R.S.; Duff, H.J.; Kavanagh, K.M.; Mitchell, L.B.; Wyse, D.G. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation. Eur. Heart J., 2008, 29(15), 1873-1880.
50. Dernellis, J.; Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am. Heart J., 2005, 150(5), 1064.
51. Watanabe, E.; Yamashita, T.; Suzuki, S.; Saikawa, T.; Hirai, M.; Yamazaki, T. Statin treatment for patients with paroxysmal atrial fibrillation. Int. Heart J., 2011, 52(2), 103-106.
52. Humphries, K.H.; Lee, M.; Sheldon, R.; Ramanathan, K.; Dorian, P.; Green, M.; Kerr, C.R. CARAF Investigators. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am. Heart J., 2007, 154(5), 908-913.
53. Naji, F.; Suran, D.; Kanic, V.; Vokac, D.; Sabovic, M. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion. Med. Sci. Monit., 2009, 15(9), CR494-498.
54. Ozaydin, M.; Varol, E.; Aslan, S.M.; Kucuktepe, Z.; Dogan, A.; Ozturk, M.; Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am. J. Cardiol., 2006, 97(10), 1490-1493.
55. Naji, F.; Suran, D.; Kanic, V.; Vokac, D.; Sabovic, M. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion. Int. Heart J., 2009, 50(2), 153-160.
56. Almroth, H.; Hoglund, N.; Boman, K.; Englund, A.; Jensen, S.; Kjellman, B.; Tornvall, P.; Rosenqvist, M. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur. Heart J., 2009, 30(7), 827-833.
57. Negi, S.; Shukrullah, I.; Veledar, E.; Bloom, H.L.; Jones, D.P.; Dudley, S.C. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J. Cardiovasc. Electrophysiol., 2011, 22(4), 414-419.
58. Al Chekakie, M.O.; Akar, J.G.; Wang, F.; Al Muradi, H.; Wu, J.; Santucci, P.; Varma, N.; Wilber, D.J. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J. Cardiovasc. Electrophysiol., 2007, 18(9), 942-946.
59. Richter, B.; Derntl, M.; Marx, M.; Lercher, P.; Gossinger, H.D. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am. Heart J., 2007, 153(1), 113-119.
60. Patel, D.; Mohanty, P.; Di Biase, L.; Wang, Y.; Shaheen, M.H.; Sanchez, J.E.; Horton, R.P.; Gallinghouse, G.J.; Zagrodzky, J.D.; Bailey, S.M.; Burkhardt, J.D.; Lewis, W.R.; Diaz, A.; Beheiry, S.; Hongo, R.; Al-Ahmad, A.; Wang, P.; Schweikert, R.; Natale, A. The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in postmenopausal females. Europace, 2010, 12(3), 322-330.